Regeneron and Sanofi Report the US FDA’s Approval of Dupixent for Chronic Spontaneous Urticaria
Shots:
- The US FDA has approved Dupixent to treat CSU pts (≥12yrs.), who were symptomatic despite H1 antihistamine treatment based on 2 P-III (Study A & C) trials from LIBERTY-CUPID program; regulatory review ongoing in EU & other regions
- Study A & C assessed Dupixent (loading dose then 300mg Q2W; pts weighing <60kg received 200mg) as an add-on therapy vs PBO in 136 & 148 CSU pts (≥6yrs.), incl. biologic-naïve pts, meeting their 1EP & key 2EPs of reduced itch severity & urticaria activity at 24wks.
- Study B did not meet its 1EP but provided additional safety data on Dupixent in 108 pts (≥12yrs.) with inadequate response or intolerance to anti-IgE therapy who remained symptomatic despite antihistamine use; data from Study A & B was published in The JACI
Ref: Regeneron | Image: Regeneron & Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
